The Pharma Data

MARCH 26, 2021

The adverse reactions observed in BLISS-LN were consistent with the known safety profile of Benlysta administered intravenously plus standard therapy in patients with SLE. positive anti-dsDNA and low complement) despite standard therapy. positive anti dsDNA and low complement) despite standard therapy. About the BLISS-LN study.

Therapies 52

Therapies Disease Treatment Vaccine 52

The Pharma Data

MAY 5, 2021

GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe, in addition to systemic lupus erythematosus (SLE).

Therapies 52

Therapies Disease Treatment International 52

The Pharma Data

MAY 13, 2021

I came across your package through Eric Cressey’s newsletter (I personally completed his Max Strength program and achieved great results) and immediately bought the webinars. Nutritional Therapy Practitioner. 2003 ACE Personal Trainer of the Year. What I didn’t realize at the time was MIR was the tip of the iceberg.

Production 52

Production Treatment Vaccine Research 52

Drug & Device Law

MAY 30, 2022

The plaintiffs’ causation allegations foundered in Himes because the treating physician did not believe that the claimed risks of electroconvulsive therapy were all that big of a deal, and thus did not warn about it. 1981) (applying Virginia law), both of which involved vaccines. April 1, 2022) (the companion case to this ).

Testimonials 59

Testimonials Doctors Production Laboratories 59